Overview

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

Status:
Unknown status

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and bezlotoxumab (BEZLO), an approved monoclonal antibody targeting C. difficile toxin, which has shown to reduce CID recurrence when used in combination with standard antibiotic treatment.

Phase:

Phase 4

Details

Lead Sponsor:

University of Kansas Medical Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Monoclonal
Vancomycin